unusually high release of immune-signalling molecules such as cytokines.
To test how the pattern of CAR expression affects the effectiveness of the T-cell response, Eyquem and colleagues tested four promoter sequences that drive gene expression. The promoters tested were of different strengths, and the authors also tested promoterless CARs integrated into two different gene loci. Their results demonstrate that integration of a promoterless CAR into the TRAC sequence results in a more consistent baseline level of CAR expression, more regulated expression of the CAR at both the transcriptional and protein level, and more effective antitumour responses in mouse models of leukaemia. This was probably because CAR expression driven by the natural TCR promoter avoids constitutive CAR signalling and the CAR expression is coupled to T-cell activation. It remains to be determined whether this CAR-expression approach results in any improvement in the toxicity profile of CAR T cells, which remains a substantial challenge in the clinic.
In more than 500 patient-years of follow-up from genetically modified T-cell treatment, the random integration of viral vectors has not been implicated as the cause of any cancers 10 . However, the risk is present, and the long-term follow-up required in these studies is expensive; perhaps both could be eliminated if there were sufficient confidence in the rarity of offtarget effects in the method used. If Eyquem and co-worker's approach is used, CRISPRCas9 off-target gene edits in CAR T cells are likely to occur only at defined regions of the genome, and the risks from such edits should be easier to assess, given that the technologies for identifying the frequency and location of such off-target edits are improving rapidly 11 . The use of CAR T cells has resulted in some successful clinical outcomes, especially in CD19-expressing B-cell acute leukaemias 1 . However, there is room for improvement in the treatment of some CD19-expressing lymphoma cancers and of solid tumours, for which CAR T-cell therapy has not been very effective. Treatment of some of these conditions might be hindered by T-cell exhaustion. Other researchers have combined CAR T cells with gene editing to remove exhaustion-associated inhibitory pathway proteins 12 . In the future, it might be interesting to compare how different combinations of gene knockouts (such as targeting T-cell-exhaustion pathways) and CAR integration might affect T-cell function. Such analysis could enhance our understanding of T-cell biology in a way that also illuminates therapeutic uses.
Eyquem and colleagues' strategy provides three important improvements for T-cellbased therapies. First, CAR T cells generated using their method made more-effective antitumour responses than CAR T cells generated using current standard techniques. Second, the targeted nature of their CAR integration might prove safer than random integration, which carries the potential risk of generating a harmful mutation. Third, this approach might enable off-the-shelf CAR T cells to be made that need not come from a patient's own T cells. This would enable easier and cheaper manufacture of CAR T cells, an outcome that would be particularly helpful for the treatment of severely immunocompromised patients. ■ 
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TA D H G P. B E G L E Y
C oenzyme F 430 is one of five coenzymes used by microorganisms to convert carbon dioxide to methane 1 . It belongs to the same family of naturally occurring compounds as haem, chlorophyll and cobalamin (vitamin B 12 ), which contain a characteristic molecular component known as a cyclic tetrapyrrole (Fig. 1) . However, in contrast to the relatively well-understood biosynthesis of those tetrapyrroles, the biosynthesis of co enzyme F 430 has remained an important unsolved problem. On page 78, Moore et al. 2 identify the genes that encode each of the proteins that catalyse the bio synthesis of coenzyme F 430 , and characterize the reactions required to make this coenzyme from sirohydrochlorin -a previously identified 3 advanced precursor of coenzyme F 430 .
BIOCHEMISTRY
Origin of a key player in methane biosynthesis
The biosynthesis of a coenzyme in the microbial production of methane has been determined -completing the biosynthetic pathways for the family of compounds that includes chlorophyll, haem and vitamin B 12 . See Article p.78 Human T cells can be modified in vitro to insert a sequence into the genome at a random location that encodes a genetically engineered TCR called a chimaeric antigen receptor (CAR). The CAR is designed to recognize a tumour-cell antigen, and these cells, known as CAR T cells, are being used in the clinic. If the CAR is expressed constitutively, the cells often eventually express inhibitory receptors that make the cells enter a dysfunctional state called exhaustion. b, Eyquem et al. 2 have developed a way to make CAR T cells that uses the gene-editing tool CRISPR-Cas9 to replace the cell's TCR-encoding gene with a CAR-encoding sequence flanked by a small region of TCR sequences. c, These CRISPR-Cas9-edited T cells express only one type of TCR, the CAR, and provide better antitumour responses than CAR T cells generated using conventional techniques.
The biosynthesis of methane by microorganisms has fascinated scientists for almost a century. The nickel-containing coenzyme F 430 is the most complex and mechanistically intriguing of the five coenzymes involved in methanogenesis, and is used by the enzyme methyl-coenzyme M reductase 4 . This enzyme is responsible for producing about one billion tonnes of methane per year 5 . It has been estimated that one-third of this methane escapes into the atmosphere, where it makes a substantial contribution to global warming 5 . The approach used by Moore and colleagues for unravelling the origins of coenzyme F 430 nicely demonstrates a general strategy that is increasingly used to identify biosynthetic genes. This strategy is based on three general observations: the chemical logic of metabolism can be used to predict at least some of the reactions involved in the biosynthesis of any naturally occurring molecule; representative gene sequences are now available for most enzymes that mediate biosynthetic reactions; and functionally related genes are often clustered together in the genome. Thus, biosynthetic predictions can be made and verified by searching genomes for sequences that correspond to proposed biosynthetic enzymes. Once one sequence has been found, the neighbouring genes are likely to include the other biosynthetic genes.
Moore et al. predicted that the conversion of sirohydrochlorin to coenzyme F 430 would require: the insertion of a nickel ion (Ni 2+ ) into a cyclic tetrapyrrole, a process catalysed by a chelatase enzyme; the formation of two primary amide (CONH 2 ) groups; and reduction of the cyclic tetrapyrrole. Using a known chelatase amino-acid sequence and the sequence of the primary amide-forming enzyme (an amide synthetase) involved in cobalamin biosynthesis, the authors identified candidate gene clusters in the genome sequences of several methane-producing microorganisms, including Methanosarcina barkeri, Methanomassiliicoccus intestinalis and Methanocella conradii. Each gene cluster putatively encodes a chelatase, an amide synthetase that would form amides on side chains attached to the cyclic tetrapyrrole, a second amide synthetase, and a reductase enzyme that might reduce the cyclic tetrapyrrole.
Next, Moore et al. experimentally verified the functions of the putative biosynthetic genes. They began by overexpressing each gene in the proposed F 430 biosynthetic gene cluster derived from M. intestinalis and purifying the resulting enzyme, so that its activity could be investigated. A major challenge in projects such as this is obtaining the enzymes' substrates. The investigators solved this problem by using the product of a successful enzyme reaction as the substrate for the next enzyme in the pathway. In this way, substrate synthesis was integrated into the biosynthetic investigation, avoiding the need to prepare complex substrates using chemical synthesis.
The authors identified enzymatically prepared sirohydrochlorin 6 as the substrate for the chelatase (Fig. 1) , which inserts Ni 2+ into the cyclic tetrapyrrole as predicted (individual steps in the biosynthesis are depicted in Figure 5 of the paper   2 ). The product of the reaction, Ni 2+ -sirohydrochlorin, is the substrate for the first of the two putative amide synthetases, which forms two amides on side chains to yield Ni 2+ -sirohydrochlorin a,c-diamide as its product. This is then reduced by the reductase to give Ni 2+ -hexahydrosirohydrochlorin a,c-diamide, which probably undergoes a non-enzymatic conversion to form an intermediate called seco-F 430 .
Moore and colleagues found that the final step is conversion of seco-F 430 to coenzyme F 430 by the second putative amide-forming enzyme. Although the reaction product is not an amide, the reaction shares the main features of amideformation reactions and is likely to follow a similar catalytic mechanism. The authors confirmed the identities of all the key reaction products by purifying them and characterizing them using nuclear magnetic resonance spectroscopy.
Two of the identified enzymes merit further comment. The chelatase that catalyses the Ni 2+ -insertion reaction has to bend the planar cyclic tetrapyrrole so that the ion can interact with lone pairs of electrons on nitrogen atoms in the tetrapyrrole -these lone pairs are inaccessible in the planar structure. Similar enzymes 7 that also bend the tetrapyrrole insert iron into haem, magnesium into chlorophyll, and cobalt into cobalamin during biosynthesis.
The other noteworthy enzyme is the reductase. This is the most complex enzyme in the pathway, and reduces three carbon-carbon double bonds to form six chiral centres (that is, a carbon atom attached to four different atoms or groups, which have two possible mirror-image geometric arrangements; such 'handedness' of chiral centres often governs the biological activity of naturally occurring compounds). This enzyme contains two different subunits and uses a reduced cluster of iron and sulfur atoms to mediate the reduction chemistry. These clusters are frequently used as an electron source for difficult reduction reactions in biology.
Moore and colleagues' elucidation of the biosynthetic pathway for coenzyme F 430 completes our understanding of how the major tetrapyrrole-containing natural products are constructed. It also provides crucial information about the fascinating chemistry involved in biological methane production, and sets the stage for detailed mechanistic and structural studies, which will enhance our ability to further develop the biotechnology of methane production. ■ Tadhg 2 report the enzymes and reactions required to make this coenzyme from an advanced biosynthetic precursor called sirohydrochlorin. Four enzymes are needed: a chelatase, an amide synthetase that makes primary amide (CONH 2 ) groups, a reductase enzyme that reduces the tetrapyrrole group (red), and another enzyme that catalyses the final step, the formation of ring F. The penultimate step (formation of ring E) does not seem to require enzyme catalysis. Other rings (A to D) of coenzyme F 430 are also labelled. Ni, nickel.
